AR037714A1 - Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer - Google Patents

Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer

Info

Publication number
AR037714A1
AR037714A1 ARP020104721A ARP020104721A AR037714A1 AR 037714 A1 AR037714 A1 AR 037714A1 AR P020104721 A ARP020104721 A AR P020104721A AR P020104721 A ARP020104721 A AR P020104721A AR 037714 A1 AR037714 A1 AR 037714A1
Authority
AR
Argentina
Prior art keywords
substituted
carbon atoms
cancer
compounds
treatment
Prior art date
Application number
ARP020104721A
Other languages
English (en)
Original Assignee
Maxia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxia Pharmaceuticals Inc filed Critical Maxia Pharmaceuticals Inc
Publication of AR037714A1 publication Critical patent/AR037714A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

La presente se refiere a ciertos heterociclos sustituidos, incluyendo a los compuestos de tiazolidinona 2-sustituida y oxazolidinona 2-sustituida. Estos compuestos son útiles para el tratamiento de enfermedades relacionadas con la proliferación celular no controlada, como por ejemplo, el cáncer o las condiciones pre-cancerígenas. Los compuestos también son útiles para modular el metabolismo de los lípidos y/o carbohidratos, y tratar la diabetes Tipo ll, hiperglicemia u obesidad, y para tratar enfermedades inflamatorias como por ejemplo, la artritis. Reivindicación (1): un compuesto que tiene la estructura de fórmula (1) o (2) donde: a) Ar1 tiene la siguiente estructura de fórmula (3): donde R10 es un radical orgánico que tiene de 1 a 12 átomos de carbono, y R11, R12, R13 y R14 se seleccionan, de manera independiente, de hidrógeno, radicales inorgánicos o radicales orgánicos que tienen de 1 a 10 átomos de carbono. B) Ar2 tiene de 4 a 30 átomos de carbono y un radical arilo, arilo sustituido, heteroarilo, o heteroarilo sustituido; c) R1 es hidrogeno, hidroxi, alcoxi, alquilo o alquilo sustituido; d) la línea punteada representa un enlace presente o ausente; e) W es -S- o -O-; f) X es -S- o -O-; y g) Y es un radical orgánico que comprende de 1 a 15 átomos de carbono; o su sal aceptable para uso farmacéutico.
ARP020104721A 2001-12-06 2002-12-05 Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer AR037714A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33719501P 2001-12-06 2001-12-06

Publications (1)

Publication Number Publication Date
AR037714A1 true AR037714A1 (es) 2004-12-01

Family

ID=23319498

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104721A AR037714A1 (es) 2001-12-06 2002-12-05 Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer

Country Status (7)

Country Link
US (1) US20040097566A1 (es)
EP (1) EP1463718A1 (es)
AR (1) AR037714A1 (es)
AU (1) AU2002357098A1 (es)
CA (1) CA2469342A1 (es)
TW (1) TW200304375A (es)
WO (1) WO2003050098A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02002257A (es) 1999-08-31 2002-09-30 Maxia Pharmaceuticals Inc Bencilideno-tiazolidinadionas y analogos y su uso en el tratamiento de la diabetes.
CA2440184A1 (en) * 2001-03-07 2002-09-19 Incyte San Diego, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
EP1377559A4 (en) * 2001-03-08 2005-09-28 Incyte San Diego Inc MOLECULES ACTIVATING AN RXR RECEPTOR
US20030083357A1 (en) * 2001-08-17 2003-05-01 Magnus Pfahl Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
NZ539873A (en) * 2002-11-22 2008-09-26 Smithkline Beecham Corp Novel chemical compounds, thiazolidin-4-one, thiazol-4-one
US20040167192A1 (en) * 2003-01-16 2004-08-26 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US20050038098A1 (en) * 2003-04-18 2005-02-17 Catherine Tachdjian Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
CN100453533C (zh) * 2003-12-12 2009-01-21 中国科学院上海药物研究所 一类胰高血糖样肽－1受体激动剂及其制备方法和用途
CA2568186C (en) * 2004-05-24 2011-11-15 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
DE102004051277A1 (de) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
TW200716580A (en) * 2005-06-08 2007-05-01 Smithkline Beecham Corp (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
LV13736B (en) * 2006-12-28 2008-09-20 Vjaceslavs Tribulovics Method for manufacturing 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
US20100249165A1 (en) * 2007-06-08 2010-09-30 University Of Copenhagen Pdz domain modulators
CL2009000294A1 (es) * 2008-02-08 2009-10-23 Shlorion Pharma Inc Compuestos derivados de heterociclos aril metilideno; composicion farmaceutica que los comprende; y uso en el tratamiento del dolor neuropatico e inflamacion.
AU2009304598B2 (en) 2008-10-17 2015-01-29 Akaal Pharma Pty Ltd S1P receptors modulators and their use thereof
AU2009304596A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1P receptors modulators
CN102558088A (zh) * 2010-12-31 2012-07-11 中国科学院上海药物研究所 联苯亚甲基-2-硫代-4-噻唑酮类化合物及其制备方法和用途
ES2769181T3 (es) 2013-03-14 2020-06-24 Dart Neuroscience Cayman Ltd Compuestos de piridina y de pirazina sustituidos como inhibidores de PDE4
CN110746429B (zh) * 2018-12-10 2022-11-25 广州华睿光电材料有限公司 含金刚烷的化合物、高聚物、混合物、组合物及电子器件
CN110698426B (zh) * 2019-11-04 2022-08-23 陕西师范大学 叔丁醇钾高效催化制备1,3-苯并噻唑衍生物的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE345332T1 (de) * 1999-11-12 2006-12-15 Fujimoto Brothers Co Ltd 2-(n-cyanimino)thiazolidin-4-on derivate

Also Published As

Publication number Publication date
AU2002357098A1 (en) 2003-06-23
TW200304375A (en) 2003-10-01
WO2003050098A1 (en) 2003-06-19
EP1463718A1 (en) 2004-10-06
US20040097566A1 (en) 2004-05-20
CA2469342A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
AR037714A1 (es) Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
BR0014137A (pt) Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica
NO20061793L (no) 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer
BR9916282A (pt) Composto, uso de um um composto e método de tratamento
AR063707A1 (es) Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
CY1105915T1 (el) Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar
AR004195A1 (es) Nuevos derivados de la 5-0 desosaminil-6-0-metil-eritronolida a, su procedimiento de preparacion, compuestos intermediarios, metodo de aplicacionde los mismos para la preparacion de productos biologicamente activos.
BRPI0510666A (pt) compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação
DOP2005000076A (es) "compuestos de aril-o heteroarilamida ortosustituidos"
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
AR063706A1 (es) Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
AR073740A1 (es) Compuestos para el tratamiento de la hepatitis c
CO5690585A2 (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
CO5080782A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
ES2193874B1 (es) Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas.
YU18999A (sh) Supstituisani tricikli
BR1100636A (pt) Agente terapêutico para o mal de parkinson, e, derivado da xantina
BR0207846A (pt) Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
KR950702554A (ko) 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents)
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
DE68919945T2 (de) Substituierte beta-Diketone.
AR027035A1 (es) Pirroles sustituidos
PE20040160A1 (es) 1,2-dihidropirazol-3-onas que controlan citoquinas inflamatorias
DK0550493T3 (da) Anthelmintiske og anticoccidiske 3-carbamoyl-4-hydroxycoumariner, fremgangsmåde til deres anvendelse og sammensætninger

Legal Events

Date Code Title Description
FA Abandonment or withdrawal